These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 1614566

  • 1. [Postmenopausal estrogen substitution and the risk of atherosclerotic heart and vascular diseases].
    Dekker E, Büller HR, Kastelein JJ.
    Ned Tijdschr Geneeskd; 1992 Jun 20; 136(25):1197-200. PubMed ID: 1614566
    [No Abstract] [Full Text] [Related]

  • 2. [Hormone substitution in the menopause: effect on lipids and cardiovascular risk].
    Keller U.
    Schweiz Rundsch Med Prax; 1991 Apr 16; 80(16):413-7. PubMed ID: 2038637
    [Abstract] [Full Text] [Related]

  • 3. Noncontraceptive estrogen use and cardiovascular disease.
    Bush TL, Barrett-Connor E.
    Epidemiol Rev; 1985 Apr 16; 7():89-104. PubMed ID: 2996919
    [Abstract] [Full Text] [Related]

  • 4. [Postmenopausal estrogen replacement therapy and the risk of atherosclerotic cardiovascular diseases].
    Donders SH.
    Ned Tijdschr Geneeskd; 1992 Jul 25; 136(30):1478. PubMed ID: 1436167
    [No Abstract] [Full Text] [Related]

  • 5. [Quantitative evaluation of the cardiovascular risk associated with hormone substitution therapy during menopause].
    Scarabin PY, Plu-Bureau G.
    Arch Mal Coeur Vaiss; 1993 Feb 25; 86(2):243-8. PubMed ID: 8363427
    [Abstract] [Full Text] [Related]

  • 6. Do the cardiovascular disease risks and benefits of oral versus transdermal estrogen therapy differ between perimenopausal and postmenopausal women?
    Clarkson TB, Karas RH.
    Menopause; 2007 Feb 25; 14(6):963-7. PubMed ID: 17909452
    [No Abstract] [Full Text] [Related]

  • 7. Lipid and lipoprotein changes in relation to oral contraception and hormonal replacement therapy.
    Burkman RT.
    Fertil Steril; 1988 May 25; 49(5 Suppl 2):39S-50S. PubMed ID: 3282934
    [Abstract] [Full Text] [Related]

  • 8. [Postmenopausal estrogen therapy and cardiovascular disease].
    Tepper R, Goldberger S, May J, Cohen I, Beith Y.
    Harefuah; 1991 Jun 02; 120(11):653-7. PubMed ID: 1937214
    [No Abstract] [Full Text] [Related]

  • 9. Lipids, atherosclerosis, and the postmenopausal woman. A clinical perspective.
    Shewmon DA.
    Obstet Gynecol Clin North Am; 1994 Jun 02; 21(2):337-55. PubMed ID: 7936548
    [Abstract] [Full Text] [Related]

  • 10. Estrogen replacement therapy at menopause. How benefits outweigh risks.
    Griffing GT, Allen SH.
    Postgrad Med; 1994 Oct 02; 96(5):131-40. PubMed ID: 7937412
    [Abstract] [Full Text] [Related]

  • 11. [Effects of estrogens and progestogens on the lipid profile in postmenopausal hypogonadism].
    García L, Hernández I, Cervera Aguilar R, Ayala AR.
    Ginecol Obstet Mex; 2001 Sep 02; 69():351-4. PubMed ID: 11816532
    [Abstract] [Full Text] [Related]

  • 12. [Further recognize the benefit and risk of postmenopausal hormone replacement therapy on atherosclerotic cardiovascular diseases].
    Zhang Y.
    Zhonghua Fu Chan Ke Za Zhi; 2002 Jun 18; 37(6):321-3. PubMed ID: 12947970
    [No Abstract] [Full Text] [Related]

  • 13. Arteriosclerosis risk. The roles of oral contraceptives and postmenopausal estrogens.
    Knopp RH.
    J Reprod Med; 1986 Sep 18; 31(9 Suppl):913-21. PubMed ID: 3772911
    [Abstract] [Full Text] [Related]

  • 14. [Hormone replacement therapy and cardiovascular risk in postmenopausal women].
    Kovacev-Zavisić B, Icin T, Kovacev N.
    Med Pregl; 2009 Sep 18; 62 Suppl 3():85-90. PubMed ID: 19702123
    [Abstract] [Full Text] [Related]

  • 15. Atherosclerotic risk factors in cardiovascular disease.
    LaRosa JC.
    J Reprod Med; 1986 Sep 18; 31(9 Suppl):906-12. PubMed ID: 3772910
    [Abstract] [Full Text] [Related]

  • 16. [Estrogens and cardiovascular diseases: should current guidelines be changed?].
    Beller F, Theiss W.
    Zentralbl Gynakol; 1994 Sep 18; 116(8):441-8. PubMed ID: 7941812
    [Abstract] [Full Text] [Related]

  • 17. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr 18; 12(64):65-9. PubMed ID: 12674130
    [Abstract] [Full Text] [Related]

  • 18. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal.
    Störk S, van der Schouw YT, Grobbee DE, Bots ML.
    Trends Endocrinol Metab; 2004 Mar 18; 15(2):66-72. PubMed ID: 15036252
    [Abstract] [Full Text] [Related]

  • 19. Low-dose oral contraceptives: progestin potency, androgenicity, and atherogenic potential.
    Ellis J.
    Clin Ther; 1986 Mar 18; 8(6):607-18. PubMed ID: 3539347
    [Abstract] [Full Text] [Related]

  • 20. Health risks after cessation of postmenopausal hormone therapy.
    Pines A, Sturdee D, Birkhäuser M, International Menopause Society.
    Climacteric; 2008 Jun 18; 11(3):179-80. PubMed ID: 18568782
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.